Janux Therapeutics (JANX) Operating Margin (2020 - 2025)
Historic Operating Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 352.51%.
- Janux Therapeutics' Operating Margin rose 78119500.0% to 352.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 1442.88%, marking a year-over-year decrease of 7841200.0%. This contributed to the annual value of 933.58% for FY2024, which is 307100.0% down from last year.
- As of Q3 2025, Janux Therapeutics' Operating Margin stood at 352.51%, which was up 78119500.0% from 8164.46% recorded in Q3 2024.
- Janux Therapeutics' Operating Margin's 5-year high stood at 155.36% during Q2 2024, with a 5-year trough of 8164.46% in Q3 2024.
- Moreover, its 5-year median value for Operating Margin was 843.51% (2021), whereas its average is 1338.23%.
- Its Operating Margin has fluctuated over the past 5 years, first crashed by -75362200bps in 2024, then soared by 78119500bps in 2025.
- Janux Therapeutics' Operating Margin (Quarter) stood at 834.78% in 2021, then rose by 23bps to 642.04% in 2022, then dropped by -2bps to 655.71% in 2023, then tumbled by -1145bps to 8164.46% in 2024, then soared by 96bps to 352.51% in 2025.
- Its Operating Margin was 352.51% in Q3 2025, compared to 8164.46% in Q3 2024 and 155.36% in Q2 2024.